Gilead Sciences (GILD) Cash & Equivalents (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Cash & Equivalents data on file, last reported at $7.6 billion in Q1 2026.

• Quarterly Cash & Equivalents fell 3.76% year-over-year to $7.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 billion (down 3.76% YoY) and the FY2025 annual result came in at $7.6 billion, down 24.29% from the prior year.
• Cash & Equivalents rose to $7.6 billion in Q1 2026, from $7.6 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $10.0 billion in Q4 2024 to a low of $2.8 billion in Q2 2024.
• A 5-year average of $5.9 billion and a median of $5.4 billion in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 51.4% — and 2025, when it surged 85.57%.
• Tracing GILD's Cash & Equivalents over 5 years: stood at $5.4 billion in 2022, then climbed by 12.44% to $6.1 billion in 2023, then soared by 64.19% to $10.0 billion in 2024, then retreated by 24.29% to $7.6 billion in 2025, then increased by 0.85% to $7.6 billion in 2026.
• The last three Cash & Equivalents figures came in at $7.6 billion (Q1 2026), $7.6 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.